HemoSonics’ Quantra Hemostasis System Earns Silver at the 2026 Edison Awards for Advancing Obstetric Care
HemoSonics LLC, a medical device innovator specializing in acute bleeding management, has earned significant industry recognition for its advancements in maternal healthcare. The company announced that its Quantra® Hemostasis System for obstetric procedures received a Silver award at the prestigious Edison Awards 2026 in the Women’s Health and Reproductive Innovations category. This distinction highlights the growing importance of technological innovation in addressing one of the most pressing challenges in global maternal health—severe bleeding during and after childbirth.
At the center of this recognition is the Quantra Hemostasis System, a breakthrough platform that has become the first and only viscoelastic testing (VET) device cleared by the U.S. Food and Drug Administration specifically for use in obstetric bleeding. This regulatory milestone marks a significant step forward in equipping clinicians with tools designed to address the unique physiological challenges associated with pregnancy and childbirth. By delivering rapid, real-time insights into a patient’s coagulation status, the system enables healthcare providers to make informed, timely decisions that can be critical in emergency scenarios.
One of the most urgent clinical conditions this technology aims to address is postpartum hemorrhage (PPH), a complication that remains the leading cause of maternal mortality worldwide. According to data from the World Health Organization, more than 14 million women experience PPH each year, resulting in approximately 70,000 deaths globally. Despite advances in obstetric care, the burden of maternal mortality remains disproportionately high in many regions. Even in developed healthcare systems, the challenge persists. In the United States, maternal mortality rates stand at 21.1 deaths per 100,000 live births—nearly double the average across countries in the Organisation for Economic Co-operation and Development—with bleeding accounting for more than 10% of these fatalities.
The Quantra Hemostasis System is designed to address these challenges by transforming how clinicians assess and manage coagulation during obstetric procedures. Unlike conventional laboratory-based coagulation tests, which can be time-consuming and may not fully capture the dynamic nature of clot formation, the Quantra platform provides a comprehensive, whole-blood analysis directly at the point of care. This capability is particularly valuable in obstetric settings, where rapid clinical decisions are often required to prevent complications from escalating.
The system comprises the Quantra Hemostasis Analyzer along with specialized QPlus® and QStat cartridges. Notably, the QStat Cartridge received 510(k) clearance from the FDA in August 2025 for expanded use in peripartum obstetric procedures, further validating the system’s clinical utility. This expansion allows the platform to be used more broadly in managing bleeding risks during labor and delivery, enhancing its relevance in maternity wards and surgical suites.
A key differentiator of the Quantra system is its use of SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound-based technology. This innovative approach measures the viscoelastic properties of a patient’s blood sample, offering detailed insights into clot strength, stability, and overall coagulation function. By analyzing these parameters in real time, clinicians can identify specific coagulation abnormalities and tailor interventions accordingly.
Importantly, the system delivers results in less than 15 minutes, a critical advantage in emergency situations such as postpartum hemorrhage, where every minute can be the difference between life and death. With rapid access to actionable data, healthcare providers can implement targeted therapies, optimize the use of blood products, and reduce unnecessary transfusions. This not only improves patient outcomes but also contributes to more efficient resource utilization within healthcare systems.
Ease of use is another defining feature of the Quantra platform. Designed with frontline clinicians in mind, the system requires minimal maintenance and is straightforward to operate and interpret. This accessibility ensures that it can be effectively integrated into a wide range of clinical environments, from large academic medical centers to smaller community hospitals. By simplifying complex coagulation analysis, the system empowers a broader range of healthcare professionals to deliver high-quality, evidence-based care.
Francesco Viola, Founder and Chief Scientific Officer of HemoSonics, emphasized the company’s commitment to addressing maternal mortality through innovation. He noted that the recognition at the Edison Awards reflects not only the technological advancement of the Quantra system but also its real-world impact on patient care. Since the recent expansion of the platform to include obstetric applications, an increasing number of leading hospitals across the United States have adopted the technology to support safer deliveries and improve maternal outcomes.
The Edison Awards themselves are among the most respected honors in the field of innovation and product development. Named after the legendary inventor Thomas Edison, the awards celebrate excellence across multiple dimensions, including design, functionality, and societal impact. Each year, thousands of submissions from around the world are evaluated by an independent panel of experts, including scientists, engineers, designers, and industry leaders. Winners are selected based on their ability to address real-world challenges and deliver meaningful value to users.
HemoSonics’ achievement in 2026 builds on its previous success at the Edison Awards, where the company also received Silver recognition in 2024 in the health, medical, and biotechnology category. This consistent acknowledgment underscores the company’s role as a leader in the field of hemostasis management and its ongoing commitment to advancing patient care through innovation.
Looking ahead, the growing adoption of technologies like the Quantra Hemostasis System signals a broader shift toward precision medicine in obstetrics and beyond. By leveraging real-time data and advanced analytics, clinicians can move away from generalized treatment approaches and instead deliver personalized care tailored to each patient’s unique physiological profile.
In conclusion, the recognition of HemoSonics at the Edison Awards 2026 reflects both the technological excellence of the Quantra Hemostasis System and its potential to make a meaningful difference in maternal health outcomes. As postpartum hemorrhage continues to pose a significant global health challenge, innovations that enable faster diagnosis, more precise treatment, and improved clinical decision-making will be essential in reducing maternal mortality and ensuring safer childbirth experiences worldwide.
About HemoSonics
HemoSonics, LLC is a medical device technology company focused on acute bleeding management, improving patient care and reducing overall medical costs. The Quantra Hemostasis System, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System’s easy, fast interpretation enables simple, more efficient bleeding management at the point of care and in the laboratory.
Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to advancing research in thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit HemoSonics.com to learn more.
About the Edison Awards
Established in 1987, the Edison Awards recognize, honor, and foster innovation and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design and innovation. Past award recipients include Jony Ive, Martha Stewart, Carmichael Roberts and companies leading in innovation, including Nest, now part of Google, AMD, Intel, Naqi, 3M and Cargill. For more information, visit www.edisonawards.com.
Source Link:https://www.businesswire.com/
